Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: ABILIFY MAINTENA
Published 2025-12-23 · Last reviewed 2025-12-30 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Aripiprazole monohydrate (Abilify Maintena) is a monthly LAI formulation of aripiprazole used for schizophrenia and bipolar I maintenance.
It is a D2/D3 partial agonist antipsychotic with a comparatively lower metabolic and prolactin burden than some other SGAs, but Akathisia/restlessness and insomnia can limit tolerability.
The depot formulation provides sustained exposure between visits and is often selected when relapse risk is driven by inconsistent daily dosing. Clinic workflow (missed-dose protocols, injection scheduling, and documentation) is a major determinant of real-world effectiveness.
For interval comparisons across depot options, see the LAI Navigator and the compare view.
Aripiprazole monohydrate is commonly chosen when teams want an aripiprazole-class partial agonist with a predictable monthly injection schedule. The long half-life can support adherence but also extends the duration of adverse effects after dose changes, which influences tolerability planning.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Aripiprazole stabilizes dopamine and serotonin signaling through partial agonism and selective antagonism.
Dopamine D2/D3 partial agonism can attenuate hyperdopaminergic pathways linked to positive symptoms while supporting cortical dopaminergic tone relevant to negative symptoms. Serotonin 5-HT1A partial agonism and 5-HT2A antagonism contribute to mood-stabilizing effects.